Oxaliplatin Injection, Solution
Product Images NDC 67457-442

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 67457-442). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A chemotherapy treatment schedule figure showing administration timing for Leucovorin 200 mg/m², 5-FU bolus 400 mg/m² over 2 to 4 minutes, 5-FU infusion 600 mg/m², and Oxaliplatin injection 85 mg/m² on Day 1 and Day 2. The timeline includes arrows indicating infusion durations and intervals between doses over a 24-hour period.*

FDA Label Image

Structural Formula (Image 02)

Chemical structure of oxaliplatin showing the platinum atom coordinated with a cyclohexane diamine ligand and an oxalate group.*

FDA Label Image

Figure 2 (Image 03)

A Kaplan-Meier survival curve chart showing Disease-Free Survival (DFS) probability over time in months up to 72 months. Two treatment arms are compared: FOLFOX4 (solid line) and LV5FU2 (dashed line). The chart includes hazard ratio, event numbers, and number of patients at risk at various time points for each arm.*

FDA Label Image

Figure 3 (Image 04)

A line graph showing Disease-Free Survival (DFS) probability over 72 months for two treatment arms: FOLFOX4 - DUKES C (solid line) and LV5FU2 - DUKES C (dashed line). The graph includes a hazard ratio with 95% confidence interval and a p-value from the logrank test, illustrating comparative DFS outcomes between treatments.*

FDA Label Image

Figure 4 (Image 05)

A Kaplan-Meier survival curve chart that compares the percentage of patients surviving over 24 months for three chemotherapy regimens: Oxaliplatin + 5-FU/LV, Oxaliplatin + Irinotecan, and Irinotecan + 5-FU/LV. The vertical axis shows the percentage of patients surviving, and the horizontal axis shows time in months. Median survival times are indicated for each treatment group.*

FDA Label Image

50 mg Carton (Image 06)

Packaging label for Oxaliplatin Injection, USP 50 mg/10 mL (5 mg/mL) solution, for intravenous use. The label includes warnings that it is a cytotoxic agent, must be diluted, and should not be mixed with sodium chloride or chloride-containing solutions. The product is sterile, for single-use vial, Rx only, and is manufactured by Mylan Institutional LLC. Storage instructions specify to store between 20° to 25°C and protect from light.*

FDA Label Image

100 mg Carton (Image 07)

Packaging label for Oxaliplatin Injection, USP 100 mg/20 mL (5 mg/mL) from Mylan Institutional LLC. The label indicates a single-use vial, requires dilution, and notes it is a cytotoxic agent for intravenous use only. Storage instructions specify controlled room temperature and protection from light. The label includes NDC 67457-442-20 and manufacturing information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.